Prospective, observational study in Sickle Cell Diseasepatients on crizanlizumab treatment in Middle Eastcountries and India (SPOTLIGHT)

ovartis Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

试验速览

暂无简介。

•1. Male and female patients with clinical diagnosis of SCD (based on laboratory parameters)
•of any genotype.
•2. Patients newly initiated on treatment with locally approved crizanlizumab.
•3. Patients aged 16 years or older at crizanlizumab initiation.

•1. Patients who did not provide informed consent.
•2. Patients who received a stem cell transplant at the time of enrollment.
•3. Patients who participated in or participating in a clinical trial at the time of enrollment or
•in the 12 months prior to starting commercial crizanlizumab.
•4. According to the investigatorâ??s opinion, the patient is an unlikely candidate to provide an
•accurate medical history and/or to obtain long-term follow-up information for any reasons
•such as unavailability or severe concomitant illnesses.

发起方

ovartis Healthcare Pvt Ltd